KR102739782B1 - 생물학적으로 관련된 직교 사이토카인/수용체 쌍 - Google Patents

생물학적으로 관련된 직교 사이토카인/수용체 쌍 Download PDF

Info

Publication number
KR102739782B1
KR102739782B1 KR1020187010150A KR20187010150A KR102739782B1 KR 102739782 B1 KR102739782 B1 KR 102739782B1 KR 1020187010150 A KR1020187010150 A KR 1020187010150A KR 20187010150 A KR20187010150 A KR 20187010150A KR 102739782 B1 KR102739782 B1 KR 102739782B1
Authority
KR
South Korea
Prior art keywords
cell
cells
orthogonal
receptor
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187010150A
Other languages
English (en)
Korean (ko)
Other versions
KR20180049080A (ko
Inventor
케난 크리스토퍼 가르시아
조나단 소콜로스키
데이비드 베이커
크리스 킹
Original Assignee
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티
유니버시티 오브 워싱톤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102739782(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티, 유니버시티 오브 워싱톤 filed Critical 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티
Priority to KR1020247040181A priority Critical patent/KR20250004916A/ko
Publication of KR20180049080A publication Critical patent/KR20180049080A/ko
Application granted granted Critical
Publication of KR102739782B1 publication Critical patent/KR102739782B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4217—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
KR1020187010150A 2015-09-11 2016-09-07 생물학적으로 관련된 직교 사이토카인/수용체 쌍 Active KR102739782B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247040181A KR20250004916A (ko) 2015-09-11 2016-09-07 생물학적으로 관련된 직교 사이토카인/수용체 쌍

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562217364P 2015-09-11 2015-09-11
US62/217,364 2015-09-11
US201662375089P 2016-08-15 2016-08-15
US62/375,089 2016-08-15
PCT/US2016/050511 WO2017044464A1 (en) 2015-09-11 2016-09-07 Biologically relevant orthogonal cytokine/receptor pairs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247040181A Division KR20250004916A (ko) 2015-09-11 2016-09-07 생물학적으로 관련된 직교 사이토카인/수용체 쌍

Publications (2)

Publication Number Publication Date
KR20180049080A KR20180049080A (ko) 2018-05-10
KR102739782B1 true KR102739782B1 (ko) 2024-12-09

Family

ID=58240003

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187010150A Active KR102739782B1 (ko) 2015-09-11 2016-09-07 생물학적으로 관련된 직교 사이토카인/수용체 쌍
KR1020247040181A Pending KR20250004916A (ko) 2015-09-11 2016-09-07 생물학적으로 관련된 직교 사이토카인/수용체 쌍
KR1020207028947A Pending KR20210062591A (ko) 2015-09-11 2019-03-08 생물학적으로 관련된 직교 사이토카인/수용체 쌍

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247040181A Pending KR20250004916A (ko) 2015-09-11 2016-09-07 생물학적으로 관련된 직교 사이토카인/수용체 쌍
KR1020207028947A Pending KR20210062591A (ko) 2015-09-11 2019-03-08 생물학적으로 관련된 직교 사이토카인/수용체 쌍

Country Status (18)

Country Link
US (7) US10869887B2 (https=)
EP (2) EP3347056A4 (https=)
JP (5) JP7299021B2 (https=)
KR (3) KR102739782B1 (https=)
CN (4) CN117659160A (https=)
AR (1) AR114687A1 (https=)
AU (3) AU2016318621A1 (https=)
BR (1) BR112020018293A2 (https=)
CA (2) CA2998393A1 (https=)
HK (1) HK1258138A1 (https=)
IL (2) IL313413A (https=)
MX (1) MX2020009330A (https=)
PH (1) PH12020551417A1 (https=)
RU (1) RU2020133171A (https=)
SG (1) SG11202008780SA (https=)
TW (1) TW202017576A (https=)
WO (2) WO2017044464A1 (https=)
ZA (1) ZA202006168B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117659160A (zh) 2015-09-11 2024-03-08 小利兰·斯坦福大学托管委员会 生物相关正交细胞因子/受体对
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3123392A1 (en) * 2018-12-19 2020-06-25 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
WO2020187848A1 (en) * 2019-03-18 2020-09-24 Biontech Cell & Gene Therapies Gmbh Lnterleukin-2 receptor (il2r) and interleukin-2 (il2) variants for specific activation of immune effector cells
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
PH12022550326A1 (en) * 2019-08-13 2023-03-13 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
WO2021050752A1 (en) * 2019-09-11 2021-03-18 The Board Of Trustees Of The Leland Stanford Junior University Chimeric orthogonal receptor proteins and methods of use
EP4041760A4 (en) * 2019-10-08 2023-10-11 Zymeworks BC Inc. Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same
CN121517534A (zh) 2019-12-13 2026-02-13 辛德凯因股份有限公司 Il-2直向同源物及其使用方法
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
US11633488B2 (en) 2020-01-10 2023-04-25 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
AU2021208559A1 (en) * 2020-01-14 2022-07-07 Synthekine, Inc. CD122 with altered ICD STAT signaling
KR20220141299A (ko) * 2020-01-14 2022-10-19 신테카인, 인크. Il2 오르토로그 및 사용 방법
WO2021146436A2 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
CA3169095A1 (en) * 2020-03-05 2021-09-10 Kenan Christopher GARCIA Designed il-2 variants
US20230159892A1 (en) * 2020-04-06 2023-05-25 Synthekine, Inc. Engineered immune cells
CA3179414A1 (en) * 2020-04-06 2021-10-14 Synthekine, Inc. Human immune cells genomically modified to express orthogonal receptors
WO2022050401A2 (en) * 2020-09-01 2022-03-10 Takeda Pharmaceutical Company Limited Interleukin-2 muteins and uses thereof
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
JP2023549293A (ja) * 2020-10-26 2023-11-22 ネプチューン バイオサイエンシズ エルエルシー 直交ｉｌ－２１受容体／サイトカイン系
WO2022192346A1 (en) * 2021-03-09 2022-09-15 The Trustees Of The University Of Pennsylvania Selective stimulation of t cells in solid tumors using oncolytic viral delivery of orthogonal il-2
WO2022212918A1 (en) * 2021-04-02 2022-10-06 The Board Of Trustees Of The Leland Stanford Junior University Bispecific molecules and related compositions and methods
AU2022254143A1 (en) * 2021-04-07 2023-11-23 Provincial Health Services Authority Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same
AU2022306974A1 (en) 2021-07-09 2024-01-04 Bright Peak Therapeutics Ag Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
US20250288666A1 (en) * 2021-07-14 2025-09-18 Synthekine, Inc. Methods and compositions for use in cell therapy of neoplastic disease
AU2022348588A1 (en) 2021-09-17 2024-04-04 Parker Institute For Cancer Immunotherapy Switch receptors using il-9 signaling domains
EP4504247A1 (en) * 2022-04-04 2025-02-12 Gammadelta Therapeutics Ltd Novel gene armoring
EP4293040A1 (en) 2022-06-19 2023-12-20 ETH Zurich Cell line for engineering cytokine receptors
EP4724504A1 (en) * 2023-06-07 2026-04-15 FBD Biologics Limited Engineered il-7 variants and methods of use thereof
WO2025245495A1 (en) * 2024-05-24 2025-11-27 Cz Biohub Sf, Llc Selective sensitization of cancer cells to elimination by cytotoxic lymphocytes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047178A1 (en) 1998-03-20 1999-09-23 Genzyme Corporation Novel complementing receptor-ligand pairs and adoptive immunotherapy using same
US20060199250A1 (en) 2005-03-04 2006-09-07 Huimin Zhao Method for generating a mutant protein which efficiently binds a target molecule
US20140255360A1 (en) 2013-03-10 2014-09-11 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902502A (en) * 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
US20060234205A1 (en) * 2004-03-05 2006-10-19 Chiron Corporation In vitro test system for predicting patient tolerability of therapeutic agents
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
JP5703020B2 (ja) 2007-08-24 2015-04-15 ノボ ノルディスク ヘルス ケア アーゲー タンパク質を選択的に修飾するための組成物と方法
EP2560994B1 (en) * 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
US10391126B2 (en) * 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
BR122020002986A8 (pt) * 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
FI2997141T3 (fi) 2013-05-13 2022-12-15 CD19-spesifinen kimeerinen antigeenireseptori ja sen käyttöjä
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
CR20170510A (es) * 2015-04-10 2018-02-26 Amgen Inc Muteínas de interuquina 2 para la expansión de células t regulatorias
CN117659160A (zh) * 2015-09-11 2024-03-08 小利兰·斯坦福大学托管委员会 生物相关正交细胞因子/受体对
JP7422480B2 (ja) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド 制御性ｔ細胞の増殖のためのインターロイキン－２変異タンパク質
CN107746831B (zh) 2017-11-07 2019-04-23 南京北恒生物科技有限公司 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047178A1 (en) 1998-03-20 1999-09-23 Genzyme Corporation Novel complementing receptor-ligand pairs and adoptive immunotherapy using same
JP2002506980A (ja) * 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 新規の相補的レセプター−リガンド対およびそれを使用する養子免疫療法
US20060199250A1 (en) 2005-03-04 2006-09-07 Huimin Zhao Method for generating a mutant protein which efficiently binds a target molecule
US20140255360A1 (en) 2013-03-10 2014-09-11 Bellicum Pharmaceuticals, Inc. Modified caspase polypeptides and uses thereof

Also Published As

Publication number Publication date
EP3347056A1 (en) 2018-07-18
US20240374645A1 (en) 2024-11-14
EP3347056A4 (en) 2019-02-27
CA2998393A1 (en) 2017-03-16
WO2017044464A1 (en) 2017-03-16
TW202017576A (zh) 2020-05-16
CA3093472A1 (en) 2019-09-12
CN112272560B (zh) 2025-03-14
JP2018526020A (ja) 2018-09-13
AU2023203727B2 (en) 2026-04-09
JP2024054175A (ja) 2024-04-16
AU2019231997B2 (en) 2025-12-11
IL277118A (en) 2020-10-29
CN112272560A (zh) 2021-01-26
KR20210062591A (ko) 2021-05-31
EP3761997A1 (en) 2021-01-13
US20220354893A1 (en) 2022-11-10
SG11202008780SA (en) 2020-10-29
EP3761997A4 (en) 2022-08-03
JP7495385B2 (ja) 2024-06-04
US20210060068A1 (en) 2021-03-04
WO2019173773A1 (en) 2019-09-12
IL277118B1 (en) 2024-08-01
NZ741548A (en) 2025-05-30
BR112020018293A2 (pt) 2020-12-29
US10869887B2 (en) 2020-12-22
AU2023203727A1 (en) 2023-07-06
RU2020133171A (ru) 2022-04-12
AU2019231997A1 (en) 2020-10-15
ZA202006168B (en) 2022-01-26
US20180228842A1 (en) 2018-08-16
HK1258138A1 (zh) 2019-11-08
JP2021516996A (ja) 2021-07-15
US11439664B2 (en) 2022-09-13
MX2020009330A (es) 2021-02-26
US20210069243A1 (en) 2021-03-11
JP7846963B2 (ja) 2026-04-16
JP7299021B2 (ja) 2023-06-27
IL277118B2 (en) 2024-12-01
US20190183933A1 (en) 2019-06-20
JP2024037778A (ja) 2024-03-19
AR114687A1 (es) 2020-10-07
IL313413A (en) 2024-08-01
KR20180049080A (ko) 2018-05-10
KR20250004916A (ko) 2025-01-08
AU2016318621A1 (en) 2018-05-10
JP2022025129A (ja) 2022-02-09
US12005079B2 (en) 2024-06-11
CN120209111A (zh) 2025-06-27
US20260108586A1 (en) 2026-04-23
PH12020551417A1 (en) 2021-09-01
CN108430518A (zh) 2018-08-21
CN117659160A (zh) 2024-03-08

Similar Documents

Publication Publication Date Title
KR102739782B1 (ko) 생물학적으로 관련된 직교 사이토카인/수용체 쌍
AU2020346824B2 (en) Chimeric orthogonal receptor proteins and methods of use
US20260103503A1 (en) A2/ny-eso-1 specific t cell receptors and uses thereof
US20250319131A1 (en) Tunable cytokine receptor signaling domains
US20240254182A1 (en) Modified granulocyte colony-stimulating factor (g-csf) and chimeric cytokine receptors binding same
HK40080067A (en) Chimeric orthogonal receptor proteins and methods of use

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180410

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210907

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231023

Patent event code: PE09021S01D

PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240626

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240904

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241203

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241204

End annual number: 3

Start annual number: 1

PG1601 Publication of registration